Gilead Sciences

Open: 75.66 Close: 75.14 Change: -0.52

You're losing the opportunity of using an AI to get informed about Gilead Sciences Company Inc Stock.

How much time have you spent trying to decide whether investing in Gilead Sciences? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Gilead Sciences are: …

Concept Map

Semantic Network

Stock Summary

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical need. The company provides Biktarvy, Genvoya, Descovy, Descogna, Odefsey,.

Today's Summary

Gilead Sciences recently released its quarterly earnings report on April 27th. The company generated revenue of $6.35 billion during the same period, slightly surpassing the consensus estimate. Despite missing EPS estimates and experiencing a decline in revenue from last years corresponding quarter, the company still maintains a healthy net margin.

Today's News

Historical price to free cash flow ratio values for Gilead Sciences (GILD) since 2010. We have provided a few examples below that you can copy and paste to your site: Link Preview HTML Code (Click to Copy) Gilead Sciences recently released its quarterly earnings report on April 27th. The company generated revenue of $6.35 billion during the same period, slightly surpassing the consensus estimate. Despite missing EPS estimates and experiencing a decline in revenue from last years corresponding quarter, the company still maintains a healthy net margin of 20.65%. Gilead Sciences (GILD) closed the most recent trading day at $76.08, moving -0.16% from the previous trading session. The company recently declared a quarterly dividend paid on June 29th. Gilead Sciences is a biopharmaceutical company that develops and commercializes therapies for life-threatening diseases. The company was founded in 1987 and is headquartered in Foster City, California. Hepcludex® (Bulevirtide) Demonstrates Sustained Efficacy and Safety Profile in People With Chronic Hepatitis Delta Virus at 96 Weeks. Gilead Sciences to Present Latest Liver Disease Research at the European Association for the Study of the Liver (EASL) Congress 2023. Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company is looking to hire a senior medical science Liaison.

Stock Profile

"Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California."

Keywords

Are looking for the most relevant information about Gilead Sciences? Investor spend a lot of time searching for information to make investment decisions in Gilead Sciences. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Gilead Sciences are: Gilead, Sciences, company, diseases, GILD, recently, quarterly, and the most common words in the summary are: state, united, gilead, science, stock, market, job, . One of the sentences in the summary was: Gilead Sciences recently released its quarterly earnings report on April 27th. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #state #united #gilead #science #stock #market #job.